Paolo Marchetti

Istituto Dermopatico dell'Immacolata — Italy

Medicine · Health Sciences

67h-index18.3kcitations1.0kworks1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(260), Colorectal Cancer Treatments and Studies(119), Cancer Treatment and Pharmacology(100), Diabetes Treatment and Management(87), Pancreatic and Hepatic Oncology Research(82)

Publications1.0k total

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
page 1 of 52Next →

Frequent Co-authors

Paolo A. Ascierto(17), Andrea Botticelli(14), Raffaele Giusti(11), Marco Filetti(10), Giampiero Porzio(10), Corrado Ficorella(10), Paola Queirolo(10), Alessio Cortellini(9), Daniele Santini(9), Sebastiano Buti(8), Michele De Tursi(8), Federica Zoratto(8), Rita Chiari(8), Alain Gelibter(8), Michele Maio(8), Riccardo Marconcini(7), Federica De Galitiis(7), Vanna Chiarion‐Sileni(7), Michele Guida(7), Teresa Gamucci(6)